Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and PK of ATTO1310 in Adult Volunteers, Patients With Atopic Dermatitis, and Patients With Chronic Pruritus

NCT06787586 is registered in ClinicalTrials.gov with Attovia Therapeutics Inc as lead sponsor.

NCT NCT06787586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06787586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and PK of ATTO1310 in Adult Volunteers, Patients With Atopic Dermatitis, and Patients With Chronic Pruritus
Lead sponsor
Attovia Therapeutics Inc
Phase
Phase 1
Overall status
Completed
Start date
January 14, 2025
Completion date
June 11, 2026
Enrollment
108 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis (ad), atopic eczema, chronic pruritus, normal volunteers